Global Spinal Injectable Market Set to Reach USD 51.2 Billion by 2033, Driven by Non-Opioid Alternatives

Posted on 2024-09-02 by Future Market Insights in Healthcare // 0 Comments

In 2023, the global spinal injectable market is expected to be worth USD 23.3 billion. The market is expected to reach USD 51.2 billion by 2033, expanding at a 8.2% CAGR throughout the forecast period. The spinal injectable industry is on the rise due to rising demand for non-opioid alternatives. As the global healthcare landscape continues to grapple with the opioid crisis, there is a growing emphasis on finding non-opioid alternatives for pain management. Spinal injectables, such as local anesthetics, anti-inflammatory agents, and regenerative therapies, have the potential to address this need and gain prominence in the future.

Advances in imaging technology, such as fluoroscopy and ultrasound, have improved the accuracy and safety of spinal injections. Additionally, the development of specialized needles and injection devices has made the procedure less invasive and more efficient. These advancements have increased the acceptance and adoption of spinal injectables among healthcare professionals and patients. Additionally, the future holds the potential for further advancements in drug delivery systems for spinal injectables. This includes the development of sustained-release formulations, targeted delivery mechanisms, and implantable devices, which can enhance the efficacy and duration of treatment.

The spinal injectables market is expanding beyond developed regions and penetrating emerging markets. Increasing healthcare expenditure, improving healthcare infrastructure, and rising awareness about advanced treatment options in countries like India, China, and Brazil present untapped growth opportunities for spinal injectables manufacturers.

Key Takeaways from the Spinal Injectable Market:

The spinal injectable industry in the United States is predicted to reach USD 16.6 billion by 2033, increasing at a 7.7% CAGR.
The spinal injectable industry in the United Kingdom is estimated to reach a market value of USD 2.4 billion by, expanding at a CAGR of 7.2% by 2033.
During the forecast period, the spinal injectable industry in China is expected to reach a market value of USD 3.3 billion, securing a 9.0% CAGR by 2033.
The spinal injectable industry in Japan is predicted to reach USD 2.4 billion by 2033, increasing at an 8.9% CAGR.
South Korea’s spinal injectable industry is predicted to achieve a market value of USD 1.9 billion, rising at a 9.4% by 2033 CAGR during the forecast period.
With a CAGR of 8.3% from 2022 to 2033, the epidural injection is expected to dominate the spinal injectable industry.
With a CAGR of 8.0% from 2022 to 2033, the therapeutic is expected to dominate the spinal injectable industry.
With a CAGR of 8.2% from 2022 to 2033, the treatment for thoracic region is expected to dominate the spinal injectable industry.
With a CAGR of 7.8% from 2022 to 2033, the hospital is expected to dominate the spinal injectable industry.

Explore the Growing Demand for Spinal Injectable: Get All the Insights in Our Comprehensive Report!

How Does the Competition Look in the Spinal Injectable Market?

The spinal injectables sector is extremely competitive, with a large number of firms contending for market share. Numerous substantial participants in this industry comprise SpineCompany Ltd, Rouzel Pharma Pvt Ltd, Anant Pharmaceuticals Pvt. Ltd., Pfizer Inc., Wellona Pharma, Celon Laboratories Ltd., ICI HEALTHCARE PVT. LTD., Sun Pharmaceuticals Industries Ltd., Inca Healthcare Pvt. Ltd., Neon Laboratories Limited, Nicholas Piramal India Ltd., AbbVie, AstraZeneca, Hikma Pharmaceuticals PLC among other companies.

In order to take advantage of one another’s skills and increase their impact in the market, the major firms have formed tactical alliances and partnerships with other businesses are becoming more common in the industry.

The top companies invest in research and development to provide imaginative and creative products with greater efficacy, reliability, and affordability. In order to meet changing customer expectations, they are also concentrating on extending their product portfolio and bolstering their distribution strategies.

Leading firms use consolidation and mergers to strengthen their position in the market and get access to new markets. In emerging markets, notably in China and India, the sector is rapidly growing.

To boost their presence in these regions, major companies are expanding their distribution networks and building regional production sites. In order to gain a competitive edge, they are also concentrating on providing consumers in these industries with cost-effective solutions.

Key Players in the Spinal Injectable Industry:

SpineCompany Ltd
Rouzel Pharma Pvt Ltd
Anant Pharmaceuticals Pvt. Ltd.
Pfizer Inc.
Wellona Pharma
Celon Laboratories Ltd.
ICI HEALTHCARE PVT. LTD.
Sun Pharmaceuticals Industries Ltd.
Inca Healthcare Pvt. Ltd.
Neon Laboratories Limited
Nicholas Piramal India Ltd.
AbbVie
AstraZeneca
Hikma Pharmaceuticals PLC

Segmentation Analysis of the Spinal Injectable Market:

By Injection Type:

Epidural Injection
Facet Joint Injection
Sacroiliac Joint Injection
Trigger Point Injection
Provocation Discography

By Application:

Diagnostic
Therapeutic

By Spinal Region:

Cervical
Thoracic
Lumber

By End User:

Hospitals
Specialty Clinics
Regenerative Sports and Spine Centers
Diagnostic Centers
Ambulatory Surgical Centers

By Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
The Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Matched content

Editor’s pick